Research Topics
| Luis F Lopez-CortesSummaryCountry: Spain Publications
| Collaborators
|
Detail Information
Publications
Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patientsLuis F Lopez-Cortes
Unidad Clínica de Enfermedades Infecciosas, Hospitales Universitarios Virgen del Rocío Instituto de Biomedicina de Sevilla, Seville, Spain
PLoS ONE 7:e28115. 2012..We evaluated the efficacy of a lower peginterferon-α 2a dose and a shorter duration of therapy than the current standard of care in genotype 3 HCV/HIV-coinfected patients...
Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosisLuis F Lopez-Cortes
Infectious Diseases Service, University Hospital Virgen del Rocio, Seville, Spain
Clin Pharmacokinet 41:681-90. 2002..To evaluate the pharmacokinetic interactions between efavirenz and rifampicin (rifampin) in patients with HIV infection and tuberculosis...- Therapeutic drug monitoring of efavirenz: trough levels cannot be estimated on the basis of earlier plasma determinationsLuis F Lopez-Cortes
Infectious Diseases Service, Hospitales Universitarios Virgen del Rocio, Seville, Spain
J Acquir Immune Defic Syndr 39:551-6. 2005..We explore whether a limited sampling strategy could provide a good estimation of EFV trough levels and area under the curve (AUC)... 
[Pharmacology, pharmacokinetic features and interactions of atazanavir]Luis F Lopez-Cortes
Servicio de Enfermedades Infecciosas, Hospital Universitario Virgen del Rocio, Sevilla, Espana
Enferm Infecc Microbiol Clin 26:2-8. 2008....- Influence of treatment and immunological recovery on tuberculosis relapses in HIV-infected patientsL F Lopez-Cortes
Department of Infectious Diseases Service, Hospitales Universitarios Virgen del Rocio, Seville, Spain
Int J Tuberc Lung Dis 9:1385-90. 2005..Studies on tuberculosis (TB) relapse in HIV-infected patients show contradictory results regarding the optimal duration of treatment... - Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimenLuis F Lopez-Cortes
Infectious Diseases Service, Hospitales Universitarios, Virgen del Rocio, Seville, Spain
J Antimicrob Chemother 58:1017-23. 2006.... - Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patientsL F Lopez-Cortes
Instituto de Biomedicina de Sevilla, Servicio de Enfermedades Infecciosas, Hospitales Universitarios Virgen del Rocio, Seville, Spain
Clin Pharmacol Ther 84:573-80. 2008..Early therapeutic drug monitoring of pegIFN-alpha-2a levels could be beneficial in improving current treatment outcomes... - Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategyLuis F Lopez-Cortes
Infectious Diseases Service, Hospitales Universitarios Virgen del Rocio, Seville, Spain
Ther Drug Monit 29:171-6. 2007..Nevertheless, therapeutic drug monitoring is advisable to maintain appropriate levels throughout pregnancy... - Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective studyLuis F Lopez-Cortes
Servicio de Enfermedades Infecciosas, Hospitales Universitarios Virgen del Rocio, Instituto de Biomedicina de Sevilla, Seville, Spain
AIDS Res Ther 7:5. 2010..SQV 500 mg strength tablets became available at the end of 2005, thus facilitating a once-daily regimen with fewer pills, although there is very limited experience with this formulation yet... - Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patientsJuan A Pineda
Unidad de Enfermedades Infecciosas, Hospital Universitario de Valme, Sevilla, Spain
J Antimicrob Chemother 60:1347-54. 2007.... - Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patientsJuan Macias
Infectious Diseases and Microbiology Unit, Hospital Universitario de Valme, Seville, Spain
Hepatology 56:1261-70. 2012..Cumulative exposure to dideoxynucleoside analogs and increases in FPG are related with HS progression. Stetatohepatitis is frequently observed in these patients and is linked to fibrosis progression... - Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patientsJosé del Valle
Infectious Diseases Unit, Hospital Universitario de Valme, Sevilla, Spain
AIDS 22:923-30. 2008..There are no data concerning this topic in HIV/hepatitis C virus coinfected patients in whom lipid disorders are particularly common... - Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA loadKarin Neukam
Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Seville, Spain
J Hepatol 56:788-94. 2012.... - Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virusJuan Macias
Infectious Diseases Unit, Hospital Universitario de Valme, Seville, Spain
Hepatology 50:1056-63. 2009..Absent-to-mild lobular necroinflammation at baseline, achievement of response with anti-HCV treatment, and effective antiretroviral therapy are associated with slower fibrosis progression... - Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis CJuan Macias
Hospital Universitario de Valme, Seville, Spain
Antivir Ther 11:839-46. 2006..The use of PI-based HAART in HIV/HCV-coinfected patients is associated with less severe fibrosis and slower progression of fibrosis. The nucleoside analogue backbone in a HAART regimen may influence this association... - Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backboneJose A Mira
Unidad de Enfermedades Infecciosas, Hospital Universitario de Valme, Sevilla, Spain
J Antimicrob Chemother 62:1365-73. 2008.... - Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patientsJose A Mira
Unidad de Enfermedades Infecciosas y Microbiología Clinica, Hospital Universitario de Valme, Seville, Spain
AIDS 26:1721-4. 2012..The efficacy of peg-IFN with RBV in coinfected individuals with genotype 4 is significantly higher than in those with genotype 1. IL28B CC genotype is the main predictor of response in this population... - Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trialAlicia Gutiérrez-Valencia
Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocio, Universidad de Sevilla, and Hospital Universitario de Valme, Seville, Spain
Ann Intern Med 151:149-56. 2009..More than 50% of patients who start efavirenz treatment develop limiting neuropsychiatric adverse events (NPAEs)... - Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patientsNicolas Merchante
Unidad de Enfermedades Infecciosas, Hospital Universitario de Valme, Sevilla, Spain
AIDS Patient Care STDS 25:395-402. 2011..Thus, ART regimens containing FPV/r QD may be considered safe in HIV/HCV-coinfected patients, including those with cirrhosis... - Prevalence and resistance mutations of non-B HIV-1 subtypes among immigrants in Southern Spain along the decade 2000-2010Beatriz De Felipe
Laboratory of Immunovirology, Infectious Diseases Service, Instituto Ramón y Cajal de Investigaciones Cientificas IRYCIS, Hospital Universitario Ramon y Cajal, Madrid, Spain
Virol J 8:416. 2011..The objective of this study was to evaluate the prevalence of non-B subtypes circulating in a cohort of HIV-1-infected immigrants in Seville, Southern Spain and to identify drug resistance-associated mutations... - Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV/HCV co-infected patientsJuan Macias
Clinical Unit of Infectious Diseases, Department of Internal Medicine, Seville, Spain
J Hepatol 49:916-22. 2008..Because of this, we elaborated and validated cut-off values of liver stiffness (LS) to better discriminate F < or = 1 from F > or = 2 in HIV/HCV co-infected subjects to aid therapy decisions... - Discontinuation of antiretroviral therapy in patients with chronic HIV infection: clinical, virologic, and immunologic consequencesRosario C Mata
Servicio de Enfermedades Infecciosas, Hospital Universitario Virgen del Rocio, Sevilla, Spain
AIDS Patient Care STDS 19:550-62. 2005..Furthermore, there is a considerable concern about the development of drug resistance and the possibility of an incomplete immune reconstitution after the treatment interruption in some patients... - Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patientsJose A Mira
Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario de Valme, Sevilla, Spain
Antivir Ther 12:1225-35. 2007..The objective of this study was to identify predictors of severe haematological toxicity among HIV-HCV-coinfected patients treated with PEG-IFN plus RBV... - Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patientsJose A Mira
Hospital Universitario de Valme, Sevilla, Spain
Antivir Ther 12:523-9. 2007..Our objective was to determine if rapid virological response (RVR) at week 4 of therapy with peg-IFN and RBV could predict SVR among HIV/HCV-coinfected patients... - Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patientsJuan A Pineda
Unit of Infectious Diseases, Hospital Universitario de Valme, Hospital Universitario Virgen del Rocio, Seville, Spain
Clin Infect Dis 49:1274-82. 2009..To provide information about the incidence and predictors of liver decompensation and death due to liver failure in human immunodeficiency virus (HIV)-infected patients with compensated hepatitis C virus (HCV)-related cirrhosis... - Molecular epidemiology of HIV type 1 in newly diagnosed patients in southern SpainMichael J McConnell
Servicio de Enfermedades Infecciosas, Hospitales Universitarios Virgen del Rocio, Seville, Spain
AIDS Res Hum Retroviruses 24:881-7. 2008..These results elucidate the subtype diversity present in this region and suggest that the transmission of highly resistant virus variants does not occur at a high frequency in this population... - Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patientsJuan Macias
Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Seville, Spain
HIV Clin Trials 13:61-9. 2012.... - Virological and immunological stability in HIV infected patients undergoing partial-treatment interruptionRosario C Mata
Servicio de Enfermedades Infecciosas, Hospitales Universitarios Virgen del Rocio, Instituto de Biomedicina de Sevilla IBiS, Sevilla, Spain
J Clin Virol 45:362-6. 2009.... - Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patientsAlicia Gutiérrez-Valencia
Unidad Clínica de Enfermedades Infecciosas, Hospitales Universitarios Virgen del Rocío Instituto de Biomedicina de Sevilla, Seville, Spain
J Antimicrob Chemother 67:681-4. 2012..To compare intracellular and plasma etravirine concentrations when etravirine was given at 200 mg/12 h versus 400 mg/24 h and to evaluate whether the results would support once-daily dosing... - Increased regulatory T cell counts in HIV-infected nonresponders to hepatitis B virus vaccineMaria Del Mar Del Pozo Balado
Immunovirology Laboratory, Infectious Diseases Service, Clinical Biochemistry Service, Institute of Biomedicine of Seville IBIS, Virgen del Rocio University Hospital, Seville, Spain
J Infect Dis 202:362-9. 2010..These findings suggest an active role played by T(reg) cells on the immunization antigen-specific T and/or B cell responses with the final consequence of a B cell anti-HBs lower production...